Invizius Alternatives & Competitors
12 companies similar to Invizius — Fighting Inflammation at its Source
Companies similar to Invizius
ATRO Medical BV
Move away from knee pain with our Meniscus Prosthesis.
TiGenix
Pioneering regenerative solutions for joint health and mobility.
Track all Invizius competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
Clinatec
From innovative research to everyday hospital care, your pathway to the medicine of tomorr...
RedDress Ltd.
Healing is in Our Blood
Epividian, Inc.
Advancing the Mission of Medicine!
Neurotec Pharma
Advancing Novel Treatments for CNS Diseases through Microglia Cell Innovation
EraCal Therapeutics
Towards an efficacious and well-tolerated appetite-suppressant using our innovative in-viv...
KaloCyte, Inc.
Developing ErythroMer, bio-inspired artificial RBC substitute for use when stored blood is...
GyroTools LLC
Solutions and Services for Research in Magnetic Resonance Imaging and Spectroscopy
About Invizius
Invizius is a biotechnology startup with the slogan "Second Generation Complement Therapeutics." The company originated from research conducted at the University of Edinburgh, Scotland. It aims to develop Second Generation Complement Therapeutics to significantly enhance the clinical outcomes of patients with Acute Kid...
Dialysis Treatment, Extra-corporeal Treatments, Medical Research, Patient Outcomes, Research Spin-out, University Of Edinburgh, Prognosis Enhancement, Health Technology, Biomedical Engineering
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches Invizius and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at Invizius on 11 Sep 2024. The 12 companies listed here were last checked between 26 Jul 2024 and 27 Oct 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.